Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01449578 · ClinicalTrials.gov registry record · Phase 1
Dexpramipexole SAD/MAD Study
A Phase 1 study, sponsored by Knopp Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT01449578: Completed Phase 1 study, sponsored by Knopp Biosciences.
NCT01449578 is a Phase 1 study that has completed, run by Knopp Biosciences. The registered enrollment target is 63 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01449578, a Phase 1 study, has completed, sponsored by Knopp Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.
Interventions
- DRUG Dexpramipexole
- DRUG Dexpramipexole Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
What the finished NCT01449578 record still lists
NCT01449578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Dexpramipexole is the first listed.
NCT01449578 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01449578 about?
NCT01449578 is a clinical study titled "Dexpramipexole SAD/MAD Study". This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.
What is the current status of trial NCT01449578?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2011-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01449578?
The interventions under investigation include: Dexpramipexole (DRUG), Dexpramipexole Placebo (DRUG).
Who is sponsoring clinical trial NCT01449578?
This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01449578's enrollment target sits among peer trials
63 820th of 2000 higher than 1,177 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia